Myriad Genetics (MYGN) Stock Forecast, Price Target & Predictions
MYGN Stock Forecast
Myriad Genetics stock forecast is as follows: an average price target of $27.67 (represents a 0.29% upside from MYGN’s last price of $27.59) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.
MYGN Price Target
The average price target for Myriad Genetics (MYGN) is $27.67 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $22.00. This represents a potential 0.29% upside from MYGN's last price of $27.59.
MYGN Analyst Ratings
According to 13 Wall Street analysts, Myriad Genetics's rating consensus is 'Hold'. The analyst rating breakdown for MYGN stock is 0 'Strong Buy' (0.00%), 5 'Buy' (38.46%), 8 'Hold' (61.54%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Myriad Genetics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $35.00 | $27.50 | 27.27% | 26.86% |
| Aug 07, 2024 | Subbu Nambi | Guggenheim | $29.00 | $25.96 | 11.71% | 5.11% |
| Jun 26, 2024 | Sung Ji Nam | Scotiabank | $29.00 | $24.62 | 17.79% | 5.11% |
| May 13, 2024 | Jon Peterson | Piper Sandler | $28.00 | $25.07 | 11.69% | 1.49% |
| Dec 21, 2023 | David Westenberg | Piper Sandler | $23.00 | $20.49 | 12.25% | -16.64% |
| Oct 05, 2022 | Mason Carrico | Stephens | $22.00 | $20.82 | 5.67% | -20.26% |
| Apr 19, 2022 | - | Goldman Sachs | $23.00 | $23.03 | -0.13% | -16.64% |
The latest Myriad Genetics stock forecast, released on Aug 27, 2024 by Brandon Couillard from Wells Fargo, set a price target of $35.00, which represents a 27.27% increase from the stock price at the time of the forecast ($27.50), and a 26.86% increase from MYGN last price ($27.59).
Myriad Genetics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 5 |
| Avg Price Target | $35.00 | $31.00 | $28.80 |
| Last Closing Price | $27.59 | $27.59 | $27.59 |
| Upside/Downside | 26.86% | 12.36% | 4.39% |
In the current month, the average price target of Myriad Genetics stock is $35.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 26.86% increase as opposed to Myriad Genetics's last price of $27.59. This month's average price target is up 12.90% compared to last quarter, and up 21.53% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Wells Fargo | - | Overweight | Initialise |
| Aug 13, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Aug 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 07, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 07, 2024 | Guggenheim | Buy | Buy | Hold |
| Jun 26, 2024 | Scotiabank | Outperform | Sector Outperform | Initialise |
| Jun 26, 2024 | Scotiabank | - | Outperform | Initialise |
| Jun 03, 2024 | Jefferies | - | Underperform | Downgrade |
| May 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 08, 2024 | Leerink Partners | - | Outperform | Upgrade |
Myriad Genetics's last stock rating was published by Wells Fargo on Aug 27, 2024. The company Initialise its MYGN rating from "null" to "Overweight".
Myriad Genetics Financial Forecast
Myriad Genetics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $191.90M | - | $181.20M | $177.80M | $156.40M | $179.30M | $164.90M | $160.80M | $167.30M | $189.40M | $173.10M | $154.60M | $145.20M | $93.20M | $164.00M | $195.10M | $186.30M |
| Avg Forecast | $260.17M | $250.80M | $250.96M | $240.14M | $240.25M | $230.71M | $230.79M | $222.06M | $217.83M | $209.41M | $206.44M | $193.51M | $194.80M | $182.32M | $187.16M | $171.49M | $169.47M | $170.07M | $170.96M | $156.67M | $162.96M | $165.04M | $162.54M | $154.42M | $93.89M | $167.38M | $209.66M | $202.32M | $221.64M | $217.77M |
| High Forecast | $264.65M | $255.11M | $255.28M | $244.26M | $244.38M | $234.67M | $234.76M | $225.88M | $221.57M | $211.45M | $209.99M | $196.83M | $195.47M | $185.45M | $190.37M | $174.44M | $172.39M | $172.99M | $173.18M | $158.71M | $165.08M | $167.19M | $164.66M | $156.43M | $95.12M | $169.56M | $212.40M | $204.95M | $224.53M | $220.60M |
| Low Forecast | $254.12M | $244.96M | $245.13M | $234.55M | $234.66M | $225.34M | $225.42M | $216.89M | $212.76M | $205.94M | $201.63M | $189.01M | $193.36M | $178.08M | $182.80M | $167.51M | $165.53M | $166.11M | $167.48M | $153.48M | $159.64M | $161.68M | $159.23M | $151.27M | $91.98M | $163.98M | $205.40M | $198.20M | $217.13M | $213.33M |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | - | 1.06% | 1.05% | 0.92% | 1.05% | 1.05% | 0.99% | 1.01% | 1.17% | 1.12% | 1.65% | 0.87% | 0.44% | 0.81% | 0.88% | 0.86% |
Myriad Genetics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $194.80M, with a low forecast of $193.36M, and a high forecast of $195.47M. MYGN's average Quarter revenue forecast represents a 1.51% increase compared to the company's last Quarter revenue of $191.90M (Sep 23).
Myriad Genetics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-46.10M | $-297.20M | $-32.70M | $-31.30M | $-30.30M | $-4.40M | $-1.80M | $-29.70M | $55.10M | $15.10M | $-28.20M | $-34.70M | $-23.10M | $-37.60M | $-110.90M | $9.30M | $-1.20M |
| Avg Forecast | $-5.14M | $-4.95M | $-4.96M | $-4.74M | $-4.74M | $-4.56M | $-4.56M | $-4.39M | $-4.30M | $-4.14M | $-4.08M | $-21.39M | $-3.85M | $-3.60M | $-3.70M | $-19.45M | $-3.35M | $60.61M | $-3.38M | $-17.68M | $-3.22M | $-3.26M | $-3.21M | $-39.88M | $-1.85M | $-3.31M | $-4.14M | $-998.10M | $-4.38M | $-4.30M |
| High Forecast | $-5.02M | $-4.84M | $-4.84M | $-4.63M | $-4.63M | $-4.45M | $-4.45M | $-4.28M | $-4.20M | $-4.07M | $-3.98M | $-17.11M | $-3.82M | $-3.52M | $-3.61M | $-15.56M | $-3.27M | $72.73M | $-3.31M | $-14.14M | $-3.15M | $-3.19M | $-3.14M | $-31.91M | $-1.82M | $-3.24M | $-4.06M | $-798.48M | $-4.29M | $-4.21M |
| Low Forecast | $-5.23M | $-5.04M | $-5.04M | $-4.82M | $-4.83M | $-4.63M | $-4.64M | $-4.46M | $-4.38M | $-4.18M | $-4.15M | $-25.67M | $-3.86M | $-3.66M | $-3.76M | $-23.34M | $-3.40M | $48.49M | $-3.42M | $-21.21M | $-3.26M | $-3.30M | $-3.25M | $-47.86M | $-1.88M | $-3.35M | $-4.19M | $-1.20B | $-4.43M | $-4.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.80% | 80.41% | 1.68% | 9.35% | -0.50% | 1.30% | 0.10% | 9.23% | -16.91% | -4.70% | 0.71% | 18.71% | 6.99% | 9.08% | 0.11% | -2.12% | 0.28% |
5 analysts predict MYGN's average Quarter EBITDA for Dec 21 to be $-3.22M, with a high of $-3.15M and a low of $-3.26M. This is -105.84% lower than Myriad Genetics's previous annual EBITDA (Sep 21) of $55.10M.
Myriad Genetics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-61.30M | $-116.10M | $-54.70M | $-42.30M | $-35.10M | $-14.10M | $-20.50M | $-7.60M | $24.60M | $-4.70M | $-39.50M | $-44.20M | $-15.20M | $-55.40M | $-115.20M | $-8.30M | $-20.60M |
| Avg Forecast | $12.87M | $10.79M | $10.57M | $8.83M | $7.85M | $6.06M | $4.85M | $3.50M | $2.63M | $1.39M | $-955.53K | $-35.08M | $1.16M | $-6.19M | $-6.64M | $-31.89M | $-13.38M | $27.06M | $2.05M | $-28.99M | $-1.94M | $-1.46M | $-8.28M | $-55.86M | $-38.13M | $614.25K | $25.08M | $-1.04B | $38.19M | $35.51M |
| High Forecast | $13.16M | $11.03M | $10.81M | $9.02M | $8.03M | $6.20M | $4.96M | $3.58M | $2.68M | $1.42M | $-926.64K | $-28.07M | $1.19M | $-6.00M | $-6.44M | $-25.51M | $-12.97M | $32.47M | $2.08M | $-23.19M | $-1.89M | $-1.42M | $-8.06M | $-44.69M | $-37.12M | $624.65K | $25.51M | $-829.44M | $38.84M | $36.11M |
| Low Forecast | $12.48M | $10.46M | $10.26M | $8.56M | $7.61M | $5.88M | $4.70M | $3.39M | $2.55M | $1.35M | $-976.88K | $-42.10M | $580.14K | $-6.33M | $-6.79M | $-38.27M | $-13.68M | $21.65M | $1.99M | $-34.79M | $-1.97M | $-1.48M | $-8.42M | $-67.04M | $-38.77M | $598.00K | $24.42M | $-1.24B | $37.18M | $34.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.91% | 17.48% | 1.72% | 3.16% | -1.30% | -6.89% | 0.71% | 3.91% | -16.90% | 0.57% | 0.71% | 1.16% | -24.75% | -2.21% | 0.11% | -0.22% | -0.58% |
Myriad Genetics's average Quarter net income forecast for Dec 21 is $-1.94M, with a range of $-1.97M to $-1.89M. MYGN's average Quarter net income forecast represents a -107.89% decrease compared to the company's last Quarter net income of $24.60M (Sep 21).
Myriad Genetics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $170.40M | $140.70M | $151.70M | $146.50M | $130.50M | $127.10M | $110.60M | $139.30M | $180.20M | $134.80M | $145.50M | $132.90M | $124.10M | $107.40M | $132.90M | $135.60M | $135.50M |
| Avg Forecast | $199.37M | $192.19M | $192.31M | $184.02M | $184.10M | $176.79M | $176.85M | $170.16M | $166.92M | $160.47M | $158.19M | $189.27M | $149.28M | $139.71M | $143.42M | $131.42M | $129.87M | $130.32M | $131.00M | $156.42M | $124.88M | $126.47M | $124.56M | $118.33M | $71.95M | $128.27M | $160.67M | $155.03M | $169.84M | $166.88M |
| High Forecast | $202.80M | $195.49M | $195.62M | $187.18M | $187.27M | $179.83M | $179.89M | $173.09M | $169.79M | $162.03M | $160.91M | $227.12M | $149.79M | $142.11M | $145.88M | $133.68M | $132.10M | $132.56M | $132.71M | $187.70M | $126.50M | $128.11M | $126.18M | $119.87M | $72.89M | $129.94M | $162.76M | $157.05M | $172.06M | $169.05M |
| Low Forecast | $194.73M | $187.72M | $187.84M | $179.74M | $179.82M | $172.68M | $172.74M | $166.21M | $163.04M | $157.81M | $154.51M | $151.41M | $148.17M | $136.46M | $140.08M | $128.36M | $126.85M | $127.29M | $128.34M | $125.14M | $122.33M | $123.89M | $122.02M | $115.92M | $70.48M | $125.65M | $157.40M | $151.88M | $166.39M | $163.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.22% | 0.98% | 1.15% | 1.13% | 1.00% | 0.97% | 0.71% | 1.12% | 1.42% | 1.08% | 1.23% | 1.85% | 0.97% | 0.67% | 0.86% | 0.80% | 0.81% |
Myriad Genetics's average Quarter SG&A projection for Dec 23 is $149.28M, based on 8 Wall Street analysts, with a range of $148.17M to $149.79M. The forecast indicates a -12.40% fall compared to MYGN last annual SG&A of $170.40M (Sep 23).
Myriad Genetics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | $-0.18 | $-0.26 | $-0.10 | $0.31 | $-0.06 | $-0.52 | $-0.59 | $-0.20 | $-0.74 | $-1.55 | $-0.11 | $-0.28 |
| Avg Forecast | $0.16 | $0.13 | $0.13 | $0.11 | $0.10 | $0.07 | $0.06 | $0.04 | $0.03 | $0.02 | $-0.01 | $-0.10 | $0.01 | $-0.08 | $-0.08 | $-0.19 | $-0.16 | $-0.04 | $0.03 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.47 | $0.01 | $0.31 | $0.31 | $0.47 | $0.43 |
| High Forecast | $0.16 | $0.13 | $0.13 | $0.11 | $0.10 | $0.08 | $0.06 | $0.04 | $0.03 | $0.02 | $-0.01 | $-0.10 | $0.01 | $-0.07 | $-0.08 | $-0.19 | $-0.16 | $-0.04 | $0.03 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.45 | $0.01 | $0.31 | $0.32 | $0.47 | $0.44 |
| Low Forecast | $0.15 | $0.13 | $0.13 | $0.10 | $0.09 | $0.07 | $0.06 | $0.04 | $0.03 | $0.02 | $-0.01 | $-0.11 | $0.01 | $-0.08 | $-0.08 | $-0.20 | $-0.17 | $-0.04 | $0.02 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.47 | $0.01 | $0.30 | $0.31 | $0.45 | $0.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.93% | 17.51% | 3.47% | 3.18% | 10.75% | -7.20% | 3.13% | 4.01% | -17.44% | 0.59% | 3.44% | 1.27% | -26.67% | -2.42% | -4.93% | -0.24% | -0.65% |
According to 5 Wall Street analysts, Myriad Genetics's projected average Quarter EPS for Dec 21 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -107.65% decrease compared to MYGN previous annual EPS of $0.31 (Sep 21).
Myriad Genetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | $1.18 | $25.00 | 2018.64% | Buy |
| GH | Guardant Health | $26.79 | $57.27 | 113.77% | Buy |
| ILMN | Illumina | $129.18 | $200.82 | 55.46% | Buy |
| EXAS | Exact Sciences | $65.54 | $96.87 | 47.80% | Buy |
| PSNL | Personalis | $5.69 | $7.75 | 36.20% | Hold |
| MEDP | Medpace | $351.67 | $444.20 | 26.31% | Buy |
| CSTL | Castle Biosciences | $31.18 | $38.00 | 21.87% | Buy |
| QGEN | Qiagen | $46.36 | $52.37 | 12.96% | Buy |
| NEOG | Neogen | $16.13 | $17.50 | 8.49% | Buy |
| CDNA | CareDx | $28.87 | $31.00 | 7.38% | Buy |
| SHC | Sotera Health Company | $16.80 | $16.93 | 0.77% | Buy |
| MYGN | Myriad Genetics | $27.59 | $27.67 | 0.29% | Hold |
| NTRA | Natera | $126.51 | $114.38 | -9.59% | Buy |
| RDNT | RadNet | $67.79 | $59.67 | -11.98% | Buy |
| TWST | Twist Bioscience | $46.95 | $41.20 | -12.25% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
MYGN Forecast FAQ
Is Myriad Genetics a good buy?
No, according to 13 Wall Street analysts, Myriad Genetics (MYGN) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 38.46% of MYGN's total ratings.
What is MYGN's price target?
Myriad Genetics (MYGN) average price target is $27.67 with a range of $22 to $35, implying a 0.29% from its last price of $27.59. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Myriad Genetics stock go up soon?
According to Wall Street analysts' prediction for MYGN stock, the company can go up by 0.29% (from the last price of $27.59 to the average price target of $27.67), up by 26.86% based on the highest stock price target, and down by -20.26% based on the lowest stock price target.
Can Myriad Genetics stock reach $40?
MYGN's average twelve months analyst stock price target of $27.67 does not support the claim that Myriad Genetics can reach $40 in the near future.
What is Myriad Genetics's current price target trend?
1 Wall Street analyst forecast a $35 price target for Myriad Genetics (MYGN) this month, up 26.86% from its last price of $27.59. Compared to the last 3 and 12 months, the average price target increased by 12.36% and increased by 4.39%, respectively.
What are Myriad Genetics's analysts' financial forecasts?
Myriad Genetics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $923.8M (high $939.68M, low $902.32M), average EBITDA is $-18.244M (high $-17.819M, low $-18.557M), average net income is $22.26M (high $22.76M, low $21.59M), average SG&A $707.91M (high $720.08M, low $691.45M), and average EPS is $0.272 (high $0.278, low $0.264). MYGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1B (high $1.02B, low $978.76M), average EBITDA is $-19.789M (high $-19.329M, low $-20.129M), average net income is $43.06M (high $44.02M, low $41.76M), average SG&A $767.89M (high $781.09M, low $750.03M), and average EPS is $0.526 (high $0.538, low $0.51).
Did the MYGN's actual financial results beat the analysts' financial forecasts?
Based on Myriad Genetics's last annual report (Dec 2022), the company's revenue was $678.4M, beating the average analysts forecast of $667.16M by 1.68%. Apple's EBITDA was $-67.8M, missing the average prediction of $36.21M by -287.25%. The company's net income was $-112M, beating the average estimation of $-13.262M by 744.51%. Apple's SG&A was $514.7M, missing the average forecast of $547.61M by -6.01%. Lastly, the company's EPS was $-1.39, beating the average prediction of $-0.261 by 431.87%. In terms of the last quarterly report (Sep 2023), Myriad Genetics's revenue was $191.9M, beating the average analysts' forecast of $182.32M by 5.25%. The company's EBITDA was $-46.1M, beating the average prediction of $-3.601M by 1180.37%. Myriad Genetics's net income was $-61.3M, beating the average estimation of $-6.188M by 890.62%. The company's SG&A was $170.4M, beating the average forecast of $139.71M by 21.96%. Lastly, the company's EPS was $-0.75, beating the average prediction of $-0.0756 by 892.64%